Case ReportPublished 12 October 2026Case Report: From unresectable to resectable: successful conversion therapy with TACE, HAIC, envafolimab, and olaparib in advanced intrahepatic cholangiocarcinomaChi Ma · Kun Feng · Jun ZhouFrontiers in Oncologydoi 10.3389/fonc.2026.1935499
Case ReportPublished 6 October 2026Case Report: Long term multimodality treatment of canine hepatocellular carcinoma with serial monitoring of serum alpha-fetoproteinTae-Jung Dan · Cheol-Ho Yang · Yeon-Jin Kim · Min-Hee Kang · Mi-Ae Kang · Kwang-Sup Lee · Hee-Myung ParkFrontiers in Veterinary Sciencedoi 10.3389/fvets.2026.1942682
Original ResearchPublished 9 September 2026Covariate-adjusted AP-1 motif architecture and footprinting track olaparib-adaptive chromatin remodellingSubhajit DuttaFrontiers in Systems Biologydoi 10.3389/fsysb.2026.1859256
Original ResearchPublished 9 January 2026Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting systemElena-Mirabela Velişcu · Cecilia Cagnotta · Maria Giuseppa Sullo · Antonietta Anatriello · Francesco Salvo · Cristina ScavoneFrontiers in Drug Safety and Regulationdoi 10.3389/fdsfr.2025.1736759
Original ResearchPublished 13 November 2025Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancerAlp Inci · Isabell Witzel · Holger Moch · Sepehr Rahmani-Khajouei · Martin Zoche · Eleftherios Pierre SamartzisPathology and Oncology Researchdoi 10.3389/pore.2025.1612266
